Chatsworth, CA --Researchers recently published data that supports Glykon Technology Group’s U.S. Patent and Patent Pending revelations regarding the use of extracts of Garcinia cambogia, sources of hydroxycitric acid, which is known popularly as HCA. In patent art licensed to Renaissance Herbs, Inc., which sells HCA extracts under the brand name HCActive™, it has been disclosed how HCA helps dieters to feel more satisfied with meals while eating less and reducing between meal snacking. HCA influences how food is released from the stomach so that over weight dieters feel fuller faster and thereby return to the natural eating pattern of lean individuals. The patents reveal how HCA modulates insulin, leptin, cholecystokinin and other satiety signals. Proper use of this knowledge can help manufacturers to produce more effective diet products.
Swiss scientists in careful experiments showed that earlier explanations of the appetite-controlling actions of HCA are mistaken. HCA does not require carbohydrate sensors in the liver to influence appetite. Similarly, HCA does not enter into the brain and apparently also does not act by influencing serotonin receptors there, as has been suggested in some recent speculation.  The research of these European scientists indicates that HCA probably works, in part, by activating receptors in the stomach and in the duodenum, the first part of the small intestine. It is known that the stomach and the duodenum possess receptors that under the impact of food stimulate the release of cholecystokinin (CCK), glucagon-like peptides (GLP-1/2), gastric inhibitory peptide (GIP) and related signals into the blood stream. Some of these chemical signals activate peripheral nerves, such as the vagus nerve, whereas others travel to and act directly on the brain. The majority of these signals are integrated by the hypothalamus as part of the cephalic (i.e., head) response to food that indicates satiety. The modulation of these signals by HCA is covered by method of use claims in a pending Glykon patent licensed to Renaissance Herbs.
Just as it influences indicators of satiety, HCA similarly modulates hunger signals. The novel peptide ghrelin, which is produced predominantly in the stomach and causes an increase in food consumption, responds to a number of regulators that are influenced by HCA. Ghrelin levels are suppressed by changes in serum insulin during meals.  In an issued Glykon patent, HCA has been shown to positively modulate insulin metabolism, i.e., it improves the body’s responses to insulin.  The release of glucagon-like peptides also seems to be involved in the control of ghrelin levels. In addition, most researchers have found that various forms of sham feeding, that is, non-caloric feeding that mimics meals by increasing the load on the stomach thereby causing the release of CCK, suppress ghrelin levels just as does ingesting food.  As already noted, HCA modulates CCK. Furthermore, it has been shown that blood leptin levels are important for controlling the amount of ghrelin released. There was evidence at least as early as 2001 suggestive that reducing resistance to leptin is a primary consideration in reducing excessive ghrelin. [5, 6, 7] In an issued Glykon patent, HCA has been shown to powerfully modulate leptin metabolism, which is to say that it improves the body’s response to leptin. 
Therefore, suppression of the level of ghrelin found in the blood is brought about by the actions of insulin, leptin, CCK, GLP, GIP and related satiety signals, factors modulated by HCA and covered by Glykon Technology Group’s issued and pending US patents. This helps to explain why HCA demonstrates a significant impact in reducing between-meal snacking as well as helping dieters push away from the table earlier in the meal.
This latest pending patent covering HCA’s appetite suppression is yet another discovery by Glykon Technologies Group that is licensed for use by Renaissance Herbs, Inc. for its HCActive™ hydroxycitric acid products. The HCActive™ line will feature breakthrough products that dramatically improve the functionality and methods of use of HCA. Other licensed issued and pending patents cover the use of HCA to regulate Syndrome X (insulin metabolism), leptin, glucocorticoids, blood pressure, bone mineralization, immune response and inflammation. Renaissance Herbs, Inc. (www.renaissanceherbs.com) is an American company dedicated to the research and development of the finest and most innovative botanical health care products available today. Our 50,000 square foot factory and R & D Center in Bangalore, India provides manufacturers with potent, standardized botanical extracts backed by Good Manufacturing Practices. The company was founded in 1990 by Alex Moffett and maintains offices in Los Angeles, California; Bangkok, Thailand; and Bangalore, India.
 Leonhardt M, Hrupka BJ, Langhans W. Subdiaphragmatic vagal deafferentation fails to block the anorectic effect of hydroxycitrate. Physiol Behav. 2004 Sep 15;82(2-3):263-8.
 Erdmann J, Lippl F, Schusdziarra V. Differential effect of protein and fat on plasma ghrelin levels in man. Regul Pept. 2003 Nov 15;116(1-3):101-7.
 United States Patent 6,207,714.
 Arosio M, Ronchi CL, Beck-Peccoz P, Gebbia C, Giavoli C, Cappiello V, Conte D, Peracchi M. Effects of modified sham feeding on ghrelin levels in healthy human subjects. J Clin Endocrinol Metab. 2004 Oct;89(10):5101-4.
 Barazzoni R, Zanetti M, Stebel M, Biolo G, Cattin L, Guarnieri G. Hyperleptinemia prevents increased plasma ghrelin concentration during short-term moderate caloric restriction in rats. Gastroenterology. 2003 May;124(5):1188-92.
 Beretta E, Dube MG, Kalra PS, Kalra SP. Long-term suppression of weight gain, adiposity, and serum insulin by central leptin gene therapy in prepubertal rats: effects on serum ghrelin and appetite-regulating genes. Pediatr Res. 2002 Aug;52(2):189-98.
 Horvath TL, Diano S, Sotonyi P, Heiman M, Tschop M. Minireview: ghrelin and the regulation of energy balance--a hypothalamic perspective. Endocrinology. 2001 Oct;142(10):4163-9.
 United States Patent 6,476,071.